Market Analysis: Global Gastric Cancer Drug Market

Global gastric cancer drug market is rising gradually to an estimated value of USD 4.37 billion by 2026 registering a substantial CAGR of 9.6% in the forecast period of 2019-2026. This rise in market value can be attributed vulnerable aging population, robust drug pipeline and people adopting unhealthy lifestyle.

Few of the major competitors currently working in the gastric cancer drug market are, Imugene Limited ,  Otsuka Pharmaceuticals Co., Ltd , Immutep , F. Hoffmann-La Roche Ltd ,   Merck KGaA ,  Bristol-Myers Squibb Company , Novartis AG , Eli Lilly and Company , Sanofi S.A , Amgen Inc., Bayer AG, Celgene Corporation, Gilead Sciences, Inc., AstraZeneca, Ipsen Pharma, Takeda Pharmaceutical Company Limited, Samumed, LLC, Arbutus Biopharma, ASLAN Pharmaceuticals  and among others.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gastric-cancer-drug-market

Market Definition: Global Gastric Cancer Drug Market

The gastric cancer drug refers to malignant tumors that begin in the lining of the stomach. This gastric cancer tends to develops over many years. It usually goes undiagnosed since it does not cause any early symptoms.

According to the article published in World Cancer Research Fund, it is identified gastric cancer was responsible for fourth most common malignancy occur in men and seventh rank in women. It is estimated that over 1.00 million new cases seen in the 2018. The high rate of incidence cases occurs in the South Korea in year of 2018. Advances in available medication, accelerating demand of novel therapies and increasing number of gastric related cancer are the drivers to the market.

Market Drivers

Increase in prevalence rate of gastric cancer due to lifestyle changes
Chronic consumption of tobacco products and alcohol
Adopting an unhealthy lifestyle such as diet with high fat, spicy food, less proteins consumption and physical inactivity
Increase in obesity cases are anticipated to the result of occurrence of gastric cancer
Rising awareness about treatment and technological advancement is driving the growth of market
Increase in the rate of R&D initiatives is driving gastric cancer drug market

Market Restraints

High cost involved in the treatment
Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
Segmentation: Global Gastric Cancer Drug Market

By Type

Adenocarcinoma
Lymphoma
Gastrointestinal stromal tumor
Carcinoid tumor
Others

By Drug Type

Doxorubicin Hydrochloride
Sunitinib
Mitomycin
Imatinib
Fluorouracil
Trastuzumab
Docetaxel
Others

By Treatment

Medication
Chemotherapy
Targeted Therapy
Radiation Therapy
Immunotherapy
Surgery

By Route of administration

Oral
Injectable

By End users

Hospitals
Homecare
Specialty Clinics
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia-Pacific
Middle East & Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-gastric-cancer-drug-market

Key Developments in the Market:

On February 2019, Taiho Pharmaceutical Co., Ltd as a subsidiary of Otsuka Holdings Co., Ltd received FDA approval for Lonsurf (trifluridine/tipiracil, TAS-102) for the treatment of patient with advanced or metastatic gastric cancer, which was previously administered on first line chemotherapy
On September 2017, Merck & Co., Inc. received accelerated approval from FDA for Keytruda (pembrolizumab) for the treatment of patient with locally advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma
Competitive Analysis: Global Gastric Cancer Drug Market

Global gastric cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cystic fibrosis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa